Through
11/26
A round-up of Penn mentions in local, national, and international media.
Penn In the News
John Vasudevan of the Perelman School of Medicine says that Christian Pulisic’s “contusion” is a fancy word for a bruise to the bone or soft tissues, with recovery usually taking between one to three weeks.
Penn In the News
Susan Wachter of the Wharton School says that Blackstone’s limit on withdrawals and Wells Fargo’s mass cutting of employees are realistic pullback responses to overall economic weakness and rising interest rates.
Penn In the News
A study by Frederic Bushman of the Perelman School of Medicine and colleagues points to a human oral amoeba as the host for a recently discovered family of DNA viruses.
Penn In the News
César de la Fuente of the Perelman School of Medicine and colleagues have identified extinct antibiotic molecules in ancient mitochondrial DNA that could be revived to help fight infections.
Penn In the News
A study from the School of Veterinary Medicine finds that dogs tend to be diagnosed with diabetes more often in the winter and the northern U.S., despite the greater number of dogs living in other areas.
Penn In the News
Jason Karlawish of the Perelman School of Medicine notes the benefits and risks of experimental Alzheimer’s drug lecanemab.
Penn In the News
Daniel Yoshor of the Perelman School of Medicine says that Elon Musk’s Neuralink implant has impressive hardware but does not represent a dramatic advance in restoring or enhancing brain function.
Penn In the News
Jeremy Siegel of the Wharton School is featured on a segment of “Squawk Box” to discuss his outlook on future interest rate hikes from the Federal Reserve.
Penn In the News
A survey by Olivia Mitchell of the Wharton School and colleagues evaluated the five major financial regrets of older Americans, which increase dramatically when people are encouraged to think about how long they’re likely to live.
Penn In the News
Jason Karlawish of the Perelman School of Medicine says that the new data on experimental Alzheimer’s drug lecanemab show reason for both optimism and caution.